Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Certified by Founder
Lodge
Elevara Medicines
start up
United Kingdom
- London Area
- 24/10/2025
- Series A
- $70,000,000
Starting a new era in rheumatoid arthritis treatment.
Elevara Medicines addresses a fundamental problem in rheumatoid arthritis (RA) where patients fail to achieve disease remission through immune targeted approaches. Proliferation and activation of fibroblast-like synoviocytes (FLS) is a central part of RA pathobiology and research over the last 20 years has shown these cells are direct contributors to the disease rather than innocent bystanders. By specifically targeting these cells, Elevara Medicines aims to break the efficacy ceiling patients experience with existing immunosuppressive drugs.
- Industry Biotechnology Research
- Website https://www.elevara.com/
- LinkedIn https://www.linkedin.com/company/elevara-medicines/
CipherOwl | $15,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)